Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobira's Next-Generation CCR5 Receptor Antagonist

SAN FRANCISCO, Feb. 17 /PRNewswire/ -- Pharmacokinetic/pharmacodynamic (PK/PD) data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, show a strong relationship between drug exposure and viral suppression with this next-generation CCR5 receptor antagoni

http://digg.com/u1Ndi8